Umekawa Motoyuki, Shinya Yuki, Hasegawa Hirotaka, Kawashima Mariko, Shin Masahiro, Katano Atsuto, Minamitani Masanari, Kashio Akinori, Kondo Kenji, Saito Nobuhito
Department of Neurosurgery, The University of Tokyo Hospital, Tokyo, 113-8655, Japan.
Department of Radiology, The University of Tokyo Hospital, Tokyo, 113-8655, Japan.
J Neurooncol. 2022 Aug;159(1):201-209. doi: 10.1007/s11060-022-04058-9. Epub 2022 Jun 21.
Stereotactic radiosurgery (SRS) is a standard treatment modality for vestibular schwannomas (VSs). However, there is a paucity of data on tumor control and neurological preservation for larger VSs. We aimed to investigate the long-term effectiveness of SRS for Koos grade IV compared with I-III VSs.
We included 452 patients with VSs (50 Koos grade IV and 402 Koos grade I‒III) who were treated with SRS at our institution from 1990 to 2021. Tumor control and functional preservation were calculated using the Kaplan-Meier method and compared between groups with the log-rank test.
The median post-SRS follow-up period was 68 months. Progression-free survival rates were 91% at 5 and 10 years for Koos grade IV VSs, and 95% and 92%, respectively, for Koos grade I‒III VSs (p = 0.278). In Koos grade IV VSs, functional preservation rates of the facial and trigeminal nerves were both 96% at 5 years (both 98% for Koos grade I‒III VSs; facial, p = 0.410; trigeminal, p = 0.107). Hearing preservation rates were 61% at 5 years for Koos grade IV VSs and 78% for Koos grade I-III VSs (p = 0.645). Symptomatic transient tumor expansion was more common with Koos grade IV VSs (8.0% vs. 2.5%, p = 0.034), although all related symptoms diminished in accordance with tumor shrinkage.
SRS may contribute to long-term tumor control and adequate neurological preservation in the treatment of Koos grade IV VSs, comparable to those in the treatment of Koos grade I‒III VSs.
立体定向放射外科治疗(SRS)是前庭神经鞘瘤(VS)的标准治疗方式。然而,关于较大VS的肿瘤控制和神经功能保留的数据较少。我们旨在研究与I-III级VS相比,SRS治疗Koos IV级VS的长期疗效。
我们纳入了1990年至2021年在我们机构接受SRS治疗的452例VS患者(50例Koos IV级和402例Koos I-III级)。采用Kaplan-Meier方法计算肿瘤控制率和功能保留率,并通过对数秩检验进行组间比较。
SRS术后中位随访期为68个月。Koos IV级VS在5年和10年时的无进展生存率分别为91%,Koos I-III级VS分别为95%和92%(p = 0.278)。在Koos IV级VS中,面神经和三叉神经的功能保留率在5年时均为96%(Koos I-III级VS均为98%;面神经,p = 0.410;三叉神经,p = 0.107)。Koos IV级VS在5年时的听力保留率为61%,Koos I-III级VS为78%(p = 0.645)。Koos IV级VS更常见有症状的短暂肿瘤扩大(8.0%对2.5%,p = 0.034),尽管所有相关症状均随肿瘤缩小而减轻。
SRS在治疗Koos IV级VS时可能有助于长期肿瘤控制和充分的神经功能保留,与治疗Koos I-III级VS相当。